Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid de ...

More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of treatment with an investigational dual-target small-molecule inhibitor, ...

根据 T2T 概念，瘙痒的最佳 6 个月治疗目标是患者报告的峰值瘙痒数字评定量表（Peak Pruritus Numeric Rating Scale，PP-NRS）评分≤4 分。 那么，在实际治疗中，这些 “小目标” 能否实现呢？来自多个国家研究机构的研究人员，如德国明斯特大学医院皮肤科、美国 ...

Itch, which was assessed with the patient reported Peak Pruritus Numerical Rating Scale score ranging from 0 to 10, remained low with a mean weekly PP-NRS score of 2.9. The mean Eczema Area and ...

Additionally, the rates of achieving a weekly average reduction of = 4 points from baseline in the daily PP-NRS score were 67.3% and 60.5%, respectively. Long-term treatment with Stapokibart can ...